The impact of ionizing irradiation in vitro on the genome of peripheral blood lymphocytes of the asymptomatic carriers of the 5382insC mutation in the BRCA1 gene

M. Romanenko, D. Kurinnyi, O. Demchenko, S. Klymenko, S. Rushkovsky
Taras Shevchenko National University of Kyiv, Kyiv; National Scientific Center for Radiation Medicine of the NAMS of Ukraine, Kiev; National Scientific Center for Radiation Medicine of the NAMS of Ukraine, Kiev; National Scientific Center for Radiation Medicine of the NAMS of Ukraine, Kiev; Taras Shevchenko National University of Kyiv, Kyiv


One of the hereditary factors affecting the development of breast and ovarian cancer is the 5382insC mutation in BRCA1 gene. But, nearly 15 % of carriers of this mutation do not manifest cancer during their lifetime. At present, the features of the development of spontaneous and induced genomic instability in asymptomatic carriers of BRCA1 mutations are studied insufficiently. The aim of the work was to evaluate the effect of the 5382insC BRCA1 mutation on the radiosensitivity of lymphocytes of individuals without an established oncopathology. The cultivation of blood lymphocytes obtained from 9 women (3 individuals with the 5382insC BRCA1 mutation without established oncopathology, and 6 conditionally healthy volunteers) was carried out. Some of the cultures were irradiated with γ-quanta (IBL-237C emitter, power 2.34 Gy/min) at a dose of 1.0 Gy before cultivation. For evaluation of the relative level of DNA damage the method of Сomet assay was applied. It was found that spontaneous level of DNA damage in cultures of lymphocytes of carriers of the BRCA1 5382insC mutation was statistically significantly (p < 0.01) higher than in the control group. After exposure to ionizing radiation for lymphocyte cultures of individuals with BRCA1 5382insC mutation, a decrease (p < 0.01) in the level of cells with a high degree of DNA damage was observed while the apoptotic activity was found to be increased (p < 0.01). It has been suggested that an increase in the elimination of damaged cells due to apoptotic activity in response to the
action of genome-damaging factors is one of the effective mechanisms that can significantly reduce the likelihood of cancer in asymptomatic carriers of the BRCA1 gene mutations.


BRCA1 gene, Comet assay, apoptosis, peripheral blood lymphocytes, radiation, DNA damage

Full Text:



World Health Organization International Agency for Research on Cancer.International Classification of Diseases for Oncology, 3rd edition. Accessed March 1, 2018.URL:

World Health Organization. International Classification of Diseases, 10th revision. Accessed March 1, 2018. URL:

Copeland G, Lake A, Firth R. et al. Cancer in North America: 2010–2014. Volume One: Combined Cancer Incidence for the United States, Canada and North America. Springfield, IL: North American Association of Central Cancer Registries. 2017 June.

Torre LA, Trabert B, DeSantis CE et al. Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018 Jul; 68(4): 284-296.

Momenimovahed Z, Tiznobaik A, Taheri S. et al. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women's Health. 2019 Apr 30; 11: 287-299.

Fergus J. Couch, Michelle L. Deshano, M. Anne Blackwood et al. BRCA 1 mutations in women attending clinics that evaluate the risk of breast cancer. New England Journal of Medicine. 1997; 336: 1409–1415.

Jeffery P. Struewing, Patricia Hartge, Sholom Wacholder et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi jews. The New England Journal of Medicine. 1997; 336(20): 1401–1408.

A. V. Paradiso, M. Digennaro , M. Patruno et al. BRCA germline mutation test for all woman with ovarian cancer? BMC Cancer. 2019; 19: 641-652.

Olafur A. Stefansson, Sebastian Moran, Antonio Gomez et al. A DNA methylation-based definition of biologically distinct breast cancer subtypes. Molecular Oncology. 2015; 9(3): 555-568.

Mita P., Sun X., Fenyö D. et al. BRCA1 and S phase DNA repair pathways restrict LINE-1 retrotransposition in human cells. Nature Structural Molecular Biology. 2020; 27: 179–191.

Mary Ellen Moynahan, Joanne W Chiu, Beverly H Koller et al. BRCA1 Controls Homology-Directed DNA Repair. Molecular Cell. 1999; 4(4): 511-518.

Tarsounas, M., Sung, P. The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology. 2020; 21: 284–299.

Ashok R. Venkitaraman. Cancer Susceptibility and the Functions of BRCA1 and BRCA2. Cell. 2002 Jan 25; 108(2): 171-182.

Burlinson B. The in vitro and in vivo comet assays. Methods Molecular Biology. 2012; 817: 143–163.

A. Azqueta, S. Langie, A. Collins. 30 years of the Comet Assay: an overview with some new insights. Frontiers. 2007.

Benjamin M. Gyori, Gireedhar Venkatachalam, P.S. Thiagarajan et al. OpenComet: an automated tool for comet assay image analysis. Redox Biol. 2014 Jan 9; 2: 457-465.

S. R. Rushkovsky, D. А. Кurinnyi, O. M. Demchenko et al. Radioprotective properties of astaxanthin: The Impact on radiation induced chromosomal aberrations and DNA breaks in human lymphocytes in vitro. Ionizing radiation. Advances in research and applications. 2018; 221–240.

Rosner, B. Fundamentals of Biostatistics, Eighth Edition, Cengage Learning. 2015; 962.

D. А. Кurinnyi, S. R. Rushkovsky, O. M. Demchenko et al. Peculiarities of modification by astaxanthin the radiation-induced damages in the genome of human blood lymphocytes exposed in vitro on different stages of the mitotic cycle. Cytology and Genetics. 2018; 52(1): 40 – 45.

Кurinnyi D., Rushkovsky S., Demchenko O. et al. Astaxanthin as a modifier of genome instability after γ-radiation. Progress in Carotenoid Research. 2018; 121–138.

Ahnström G., Erixon K. Measurement of strand breaks by alkaline denaturation and hydroxyapatite chromatography, in DNA Repair. A Laboratory Manual of Research Procedures, eds Friedberg. 1981; 403–418.

Received: 15.10.2020

Revised: 16.11.2020

Signed for the press: 16.11.2020



  • There are currently no refbacks.

Лицензия Creative Commons
This journal is available according to the Creative Commons License «Attribution» («Атрибуція») 4.0 Global (CC-BY).